Evidence map›Paper›PMID 42046730›Full record

ArticleTherapeutic advances in medical oncology2026

A real-world study on the comparative effectiveness of first-line treatment regimens in advanced NSCLC patients with

Dujiang Liu, Xinyue Li, Kailai Yin, Yi Lu, Na Han, Yanjun Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dujiang LiuDepartment of Medical Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
Xinyue LiDepartment of Medical Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
Kailai YinPostgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China.
Yi LuDepartment of Clinical Nutrition, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
Na HanDepartment of Medical Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
Yanjun XuZhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, No. 1 East Banshan Road, Gongshu District, Hangzhou 310022, China.ORCID https://orcid.org/0000-0001-7187-8804

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: P-loop and αC-helix compressing ( Objectives: This study aimed to evaluate first-line treatment outcomes in patients with Design: A real-world retrospective study. Methods: This retrospective cohort study enrolled 100 patients with Results: Among the 100 patients, compared with chemotherapy, treatment with tyrosine kinase inhibitors (TKIs) significantly prolonged progression-free survival (PFS; 14.2 vs 5.2 months, hazard ratio (HR) = 0.348, Conclusion: TKIs may represent a promising first-line option for advanced NSCLC with

Indexed as

NGSNSCLCPACC mutationTKIstreatment

Identifiers

PMID42046730
PMCPMC13110311

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.